You are here
Global EUCLID Trial Will Compare Ticagrelor and Clopidogrel in Patients With Peripheral Arterial Disease
The randomized, double-blind, parallel group, multicenter study will compare the efficacy of ticagrelor (Brilinta) monotherapy with that of clopidogrel monotherapy in reducing the primary composite endpoint of CV death, MI, or ischemic stroke in patients with symptomatic AD. The patients will be randomly assigned to receive either ticagrelor 90 mg twice daily or clopidogrel 75 mg once daily.
Ticagrelor, a P2Y12 receptor antagonist, is currently approved only for the prevention of cardiovascular events in patients with acute coronary syndrome (ACS).
PAD is caused by atherosclerotic plaques that narrow the arteries in the legs and can lead to leg pain with walking. Patients with PAD also have atherosclerosis in other arteries, increasing their risk of myocardial infarction, stroke, and cardiovascular death. Severe cases of PAD can lead to critical or acute limb ischemia with unhealed sores or infections on the legs or feet, resulting in tissue death, gangrene, and ultimately amputation of the infected limb.
AstraZeneca faces the challenge of differentiating ticagrelor from clopidogrel (a generic version of Sanofi and Bristol-Myer’s Plavix) — its less costly rival in the AD marketplace.
To read more about this, visit the Reuters Web site.